Broadfin Capital’s Cidara Therapeutics CDTX Stock Holding History

Broadfin Capital’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-18,791	Closed	-$1.5M	–	49
2018 Q1	$1.5M	Sell	18,791 -24,079	-56%	-$3.29M	0.23%	47
2017 Q4	$5.83M	Buy	42,870 +1,850	+5%	+$281K	0.95%	27
2017 Q3	$6.64M	Buy	41,020 +206	+0.5%	+$29.3K	0.98%	26
2017 Q2	$6.12M	Buy	40,814 +12,670	+45%	+$1.75M	0.74%	34
2017 Q1	$4.39M	Hold	28,144	–	–	0.53%	36
2016 Q4	$5.85M	Buy	28,144 +19,800	+237%	+$4.11M	0.65%	39
2016 Q3	$1.91M	Hold	8,344	–	–	0.17%	66
2016 Q2	$1.72M	Hold	8,344	–	–	0.17%	61
2016 Q1	$2.12M	Hold	8,344	–	–	0.2%	63
2015 Q4	$2.86M	Hold	8,344	–	–	0.18%	77
2015 Q3	$2.12M	Buy	8,344 +844	+11%	+$241K	0.12%	82
2015 Q2	$2.1M	Buy	+7,500	New	+$2.31M	0.11%	89

Other funds holding CDTX

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return